Encorafenib (Braftovi)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 22:42, 28 March 2015 by Jwarner (talk | contribs) (Created page with "=General information= Class/mechanism (from [http://www.cancer.gov/drugdictionary?CdrID=712549 NCI Drug Dictionary]): An orally available Raf kinase inhibitor with potential a...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

General information

Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.

Retrieved from "https://hemonc.org/w/index.php?title=Encorafenib_(Braftovi)&oldid=7722"